Given the beneficial effects that SCFA-dependent GPR41 activation on regulation of metabolism, we suggest that modulating GPR41 by using synthetic ligands will be a promising therapeutic strategy for the treatment of metabolic disorders. This evidence concerns the gene FFAR3 and metabolic disease.